📊 RXST Key Takeaways
Is RxSight, Inc. (RXST) a Good Investment?
RxSight exhibits fundamental operational distress despite fortress balance sheet. The company is unprofitable with negative operating income of -$17.8M, declining revenue (-3.9% YoY), and burning cash operationally (-$10.9M annually). While the 76.1% gross margin demonstrates product viability, excessive operating expenses erode all margin, and the current cash position ($17.6M) provides limited runway at present burn rates.
RxSight, Inc. Key Strengths (RXST)
- Fortress balance sheet with zero long-term debt and $304M in total assets
- Exceptional gross margin of 76.1% indicates strong product pricing power and market demand
- Excellent short-term liquidity with 10.2x current ratio and 8.93x quick ratio
RXST Stock Risks: RxSight, Inc. Investment Risks
- Negative net income of -$15.9M and net margin of -51.4% with no clear path to profitability
- Declining revenue (-3.9% YoY) combined with negative operating cash flow (-$10.9M) indicates deteriorating business fundamentals
- Operating expenses unsustainable relative to revenue base; cash runway of ~18-20 months at current burn rate given limited relative cash position
- Negative ROE and ROA suggest inefficient capital deployment despite substantial asset base
Key Metrics to Watch
- Quarterly revenue trend reversal and YoY growth trajectory
- Operating margin improvement and path to operating profitability
- Operating cash flow conversion and monthly cash burn rate sustainability
RxSight, Inc. (RXST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.20x current ratio provides a solid financial cushion.
RXST Profit Margin, ROE & Profitability Analysis
RXST vs Market Sector: How RxSight, Inc. Compares
How RxSight, Inc. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RxSight, Inc. Stock Overvalued? RXST Valuation Analysis 2026
Based on fundamental analysis, RxSight, Inc. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RxSight, Inc. Balance Sheet: RXST Debt, Cash & Liquidity
RXST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: RxSight, Inc.'s revenue has grown significantly by 519% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.41 indicates the company is currently unprofitable.
RXST Revenue Growth, EPS Growth & YoY Performance
RXST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $30.9M | -$8.2M | $-0.20 |
| Q3 2025 | $30.3M | -$6.1M | $-0.16 |
| Q2 2025 | $33.6M | -$6.1M | $-0.16 |
| Q1 2025 | $29.5M | -$8.2M | $-0.20 |
| Q3 2024 | $22.2M | -$6.1M | $-0.16 |
| Q2 2024 | $20.8M | -$6.1M | $-0.16 |
| Q1 2024 | $17.5M | -$9.1M | $-0.25 |
| Q3 2023 | $12.6M | -$12.4M | $-0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RxSight, Inc. Dividends, Buybacks & Capital Allocation
RXST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for RxSight, Inc. (CIK: 0001111485)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RXST
What is the AI rating for RXST?
RxSight, Inc. (RXST) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RXST's key strengths?
Claude: Fortress balance sheet with zero long-term debt and $304M in total assets. Exceptional gross margin of 76.1% indicates strong product pricing power and market demand.
What are the risks of investing in RXST?
Claude: Negative net income of -$15.9M and net margin of -51.4% with no clear path to profitability. Declining revenue (-3.9% YoY) combined with negative operating cash flow (-$10.9M) indicates deteriorating business fundamentals.
What is RXST's revenue and growth?
RxSight, Inc. reported revenue of $30.9M.
Does RXST pay dividends?
RxSight, Inc. does not currently pay dividends.
Where can I find RXST SEC filings?
Official SEC filings for RxSight, Inc. (CIK: 0001111485) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RXST's EPS?
RxSight, Inc. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RXST's fundamental grade?
Based on our AI fundamental analysis in May 2026, RxSight, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RXST stock overvalued or undervalued?
Valuation metrics for RXST: ROE of -5.9% (sector avg: 15%), net margin of -51.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RXST's AI grade for 2026?
Our dual AI analysis gives RxSight, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RXST's free cash flow?
RxSight, Inc.'s operating cash flow is $-10.9M, with capital expenditures of $759.0K. FCF margin is -37.7%.
How does RXST compare to other Market stocks?
Vs Default sector averages: Net margin -51.4% (avg: 12%), ROE -5.9% (avg: 15%), current ratio 10.20 (avg: 1.8).